QVQ Mission
The QVQ team strives to use its extensive experience to make single-domain antibody technology available to the largest possible user base. As such, QVQ offers a broad range of budget- and eco-friendly single-domain antibody lead development services and reagents.
Close collaborations with top academic research groups and industrial partners ensure high-quality services and validation of our top-quality reagents.
Board
Chief Executive Officer
“Dedicated to use my knowledge to generate VHH to your needs to make the world a tiny step more beautiful.”
Edward Dolk
Chief Scientific Officer
“Proud to contribute our expertise, infrastructure and curiosity as a temporary extenstion of your lead development team”
Raimond Heukers
FAQs
What are the deliverables of a standard lead development project?
A lead development project at QVQ is always custom-made to meet the needs for your project. Often included are the delivery of VHH phagemid libraries, masterplates of monoclonal antibodies, including individual sequences, and delivery of 0.2 mg purified material of 10-12 lead candidates accompanied with experimental data.
Do you sacrifice the animals after immunization?
No, immunizations are done by accredited partners, and we only use a small volume of blood for serum titration and RNA extraction of PBMCs. Animals are routinely reused for new campaigns after a resting period and are not sacrificed for the purpose of antibody development projects.
How does the no-cure-no-pay work at QVQ?
A project is divided into different workpackages led by a dedicated project manager and together with the customer is decided whether the workpackage has been delivered. If not, QVQ will not invoice this workpackage. Thus, if no single-domain antibodies specific to the target of interest are found, the panning and selection workpackage will not be invoiced.
What is the success rate of lead panel antibody delivery?
Since QVQ works with a no-cure-no-pay policy, we make the effort to get high-quality antibodies out of each project. This means that if we receive good-quality immunogen and we use two animals to avoid the occasional bad responder, the success rate is >95%.
Who owns the IP of the project?
All intellectual property corresponding to the lead development project or the production, purification, and characterization of single-domain antibodies is transferred to the customer and is fully owned by the customer to allow protection and further development of the molecules.
Career
Join us at QVQ
For over a decade, we have worked as a great team to deliver the best lead candidates and research molecules possible.
We push our boundaries on a daily basis in order the technical need of our customers.
If you’re interested in joining the QVQ team as a student or
colleague, please contact us via career@qvquality.com